Evidence map›Paper›PMID 32565634›Full record

ArticleIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine2020

A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome.

Ankita Sharma, Sumit Ray, Ramya Mamidipalli, Atul Kakar, Parul Chugh, Ridhima Jain, Manvender S Ghalaut, Sangeeta Choudhury

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ankita SharmaDepartment of Research, Sir Ganga Ram Hospital, New Delhi, India.
Sumit RayDepartment of Critical Care Medicine, Artemis Hospital, Gurugram, Haryana, India.
Ramya MamidipalliDepartment of Medicine, Sir Ganga Ram Hospital, New Delhi, India.
Atul KakarDepartment of Medicine, Sir Ganga Ram Hospital, New Delhi, India.
Parul ChughDepartment of Research, Sir Ganga Ram Hospital, New Delhi, India.
Ridhima JainDepartment of Research, Sir Ganga Ram Hospital, New Delhi, India.
Manvender S GhalautDepartment of Biotechnology, University Institute of Engineering and Technology, Maharshi Dayanand University, Rohtak, Haryana, India.
Sangeeta ChoudhuryDepartment of Research, Sir Ganga Ram Hospital, New Delhi, India.
Sir Ganga Ram Hospital · INArtemis Hospitals · INMaharshi Dayanand University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDifferentiation between sepsis and systemic inflammation response syndrome (SIRS) remains a diagnostic challenge for clinicians as both may have similar clinical presentation. A quick and accurate diagnostic tool that can discriminate between these two conditions would aid in appropriate therapeutic decision-making. This prospective study was conducted to evaluate the diagnostic and prognostic utility of soluble urokinase-type plasminogen activator receptor (suPAR) and procalcitonin (PCT) in sepsis and SIRS patients. MATERIALS AND

methodsEighty-eight patients were enrolled, of which 29 were SIRS and 59 were sepsis patients. The levels of suPAR and PCT were measured on the day of admission (day 1), day 3, and day 7.

resultsThe levels of suPAR and PCT were significantly higher (

conclusionOur findings suggest that both suPAR and PCT can be used as potential test tools to differentiate between SIRS and sepsis. Procalcitonin showed significant prognostic trends to identify nonsurvivors. The soluble urokinase-type plasminogen activator receptor showed better diagnostic potential than PCT on day 1. CLINICAL SIGNIFICANCE: Both suPAR and PCT can be used as surrogate biomarkers to distinguish sepsis from SIRS. Procalcitonin showing a significant prognostic trend to identify nonsurvivors can help the clinicians to take relevant clinical decisions. Also, the use of biomarkers like PCT and suPAR could reduce the inappropriate use of antibiotics in noninfective SIRS. HOW TO CITE THIS ARTICLE: Sharma A, Ray S, Mamidipalli R, Kakar A, Chugh P, Jain R,

Indexed as

ProcalcitoninSepsisSoluble urokinase-type plasminogen activator receptorSystemic inflammation response syndrome

Identifiers

PMID32565634
PMCPMC7297249
OpenAlexW3027131815

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.